SUPN Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 16.9%. Supernus Pharmaceuticals's return on equity of 7.61% beat Corcept Therapeutics's return on equity of 23.78%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 24.12%. On the other hand Corcept Therapeutics has an analysts' consensus of $99.75 which suggests that it could grow by 78.09%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.835, which suggesting that the stock is 16.47% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.816%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Supernus Pharmaceuticals's net income of $15.3M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 23.64x while Corcept Therapeutics's PE ratio is 45.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 9.42x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 32.59%. Supernus Pharmaceuticals's return on equity of 7.61% beat Eli Lilly and's return on equity of 80.24%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 24.12%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Supernus Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Supernus Pharmaceuticals is more attractive than Eli Lilly and.

Supernus Pharmaceuticals has a beta of 0.835, which suggesting that the stock is 16.47% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Supernus Pharmaceuticals's net income of $15.3M is lower than Eli Lilly and's net income of $4.4B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 23.64x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 2.31%. Supernus Pharmaceuticals's return on equity of 7.61% beat Pfizer's return on equity of 8.91%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 24.12%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Supernus Pharmaceuticals has higher upside potential than Pfizer, analysts believe Supernus Pharmaceuticals is more attractive than Pfizer.

Supernus Pharmaceuticals has a beta of 0.835, which suggesting that the stock is 16.47% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Pfizer quarterly revenues of $17.8B. Supernus Pharmaceuticals's net income of $15.3M is lower than Pfizer's net income of $410M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 23.64x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 25.08%. Supernus Pharmaceuticals's return on equity of 7.61% beat Zoetis's return on equity of 49.71%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 24.12%. On the other hand Zoetis has an analysts' consensus of $202.58 which suggests that it could grow by 25.62%. Given that Zoetis has higher upside potential than Supernus Pharmaceuticals, analysts believe Zoetis is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.835, which suggesting that the stock is 16.47% less volatile than S&P 500. In comparison Zoetis has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.862%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.11% to investors and pays a quarterly dividend of $0.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Zoetis quarterly revenues of $2.3B. Supernus Pharmaceuticals's net income of $15.3M is lower than Zoetis's net income of $581M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 23.64x while Zoetis's PE ratio is 29.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 7.92x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.